Benzinga | Dec 13, 2021 09:53AM EST

Where IGM Biosciences Stands With Analysts

Within the last quarter, IGM Biosciences (NASDAQ:IGMS) has observed the following analyst ratings:

Bullish Somewhat Bullish Indifferent Somewhat Bearish BearishTotal Ratings 2 2 1 0 0Last 30D 2 0 1 0 01M Ago 0 0 0 0 02M Ago 0 2 0 0 03M Ago 0 0 0 0 0

In the last 3 months, 5 analysts have offered 12-month price targets for IGM Biosciences. The company has an average price target of $82.8 with a high of $126.00 and a low of $51.00.

Below is a summary of how these 5 analysts rated IGM Biosciences over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the move negative analysts are on the stock

This current average represents a 16.99% increase from the previous average price target of $99.75.

If you are interested in following small-cap stock news and performance you can start by tracking it here

or you can visit one of our exclusive small-cap events

Analyst Ratings: What Are They?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.